A. MENARINI INDUSTRIE FARMACEUTICHE RIUNITE SRL
Via Sette Santi, 1 50131 - Firenze (Firenze) Phone +39 055 56801 Fax +39 055 582771
Via Sette Santi, 1 50131 - Firenze (Firenze) Telefono +39 055 56801 Fax +39 055 582771
Everyday we put our values into action. 4 values, which have given life to Menarini and shaped its history.
Menarini is investing in advanced science and technology to develop a pipeline of new products that make a difference to the lives of patients affected by serious conditions.
MENARINI is a fully integrated privately owned pharma company with a long and successful heritage in strategic partnering across the globe. We have a profound know-how stemming from our strong R&D capabilities in key therapeutic areas, coupled with our excellence in commercial execution and our powerful direct presence on a global basis.
Our dedicated Corporate Business Development team is committed to assess and explore innovative new opportunities.
Donations of backpacks and cases for school, distribution of meals and medicines, promotion of sport, support for pregnant women and much more: being responsible for Menarini means transforming good intentions into concrete efforts. By helping others, we want to contribute to improve the world around us, starting with us.
What does it really make Menarini unique? The diversity and authenticity of our key resource - the People. Our cultural diversity helps us to drive innovation, adapt to business changes, face challenges, inspire ideas and develop our growth.
Menarini employees make all the difference, every day.
Ogni giorno mettiamo in pratica i nostri valori. 4 valori, che hanno dato vita a Menarini e ne hanno forgiato la storia.
Menarini investe continuamente nella scienza e nelle tecnologie all'avanguardia per lo sviluppo di una pipeline di nuovi prodotti che facciano la differenza nella vita dei pazienti affetti da gravi patologie.
Menarini è un’azienda privata completamente integrata con una lunga storia di collaborazioni di successo in tutto il Mondo. In Menarini abbiamo una conoscenza ed esperienza consolidata frutto della nostra capacità di Ricerca & Sviluppo nelle aree terapeutiche chiave, accompagnate da un’eccellente presenza capillare in tutto il Mondo.
Il nostro Team dedicato di Business Development è impegnato a valutare ed esplorare nuove opportunità innovative.
Dalla distribuzione di pasti e medicinali, dai kit per andare a scuola alla promozione dello sport all'aiuto per le donne in gravidanza: essere responsabili, per noi di Menarini, significa tradurre le buone intenzioni in sforzi concreti. Aiutando gli altri diamo il nostro contributo a migliorare il mondo che ci circonda, a partire da noi.
Che cosa rende davvero Menarini unica? La diversità ed autenticità del nostro valore più importante - le Persone. La nostra diversità culturale ci aiuta a guidare l'innovazione, ad adattarci ai cambiamenti di mercato, ad affrontare le sfide, ad ispirare idee e a promuovere la nostra crescita.
Chi lavora in Menarini fa la differenza, ogni giorno.
In February 2025 Tempus Al, Inc. (NASDAQ: TEM), a technology company leading the adoption of Al to advance precision medicine and patient care, and the Menarini Group, and Stemline Therapeutics, Inc., announced a new collaboration. The two companies will leverage Next – Tempus’ Al-enabled care pathway intelligence platform to support patients with HR+ HER2- metastatic breast cancer by helping clinicians to determine when an ESR1 test may be appropriate.
In December 2024 Menarini Group and lnsilico Medicine, a clinical stage generative artificial intelligence (Al)-driven biotechnology company, have entered into a second exclusive licensing collaboration granting Menarini Group global rights to develop and commercialize a preclinical small molecule targeting high unmet need in oncology.
In December 2023 Menarini Group and lnsilico Medicine, a clinical stage generative artificial intelligence (Al)-driven biotechnology company, have entered into an exclusive licensing collaboration granting Menarini Group global rights to develop and commercialize a preclinical small molecule KAT6 protein inhibitor targeting hormone sensitive cancers and other oncology indications. In 2024 the asset entered in clinical development.
In December 2021 Menarini Group was granted exclusive commercialization rights for NEXPOVIO (selinexor) in Europe, Latin America, and the CIS countries. Selinexor is a first-in-class oral Selective Inhibitor of Nuclear Export (XPO1) and currently approved in the US for multiple myeloma and diffuse large B-cell lymphoma. Selinexor was also granted the marketing authorisation in EMA, UK and other countries in multiple myeloma. Selinexor is being developed for the treatment of additional hematologic and solid tumor indications.
In July 2020 Menarini Group obtained global development and commercialization rights for elacestrant (ORSERDU), a first-in-class oral Selective Estrogen Receptor Degrader (SERD). Elacestrant is currently approved by FDA, EMA and in other countries for the treatment of postmenopausal women and men with advanced ER+/HER2- breast cancer and in clinical development in additional indications.
June 28, 2022 - Exclusive licensing deal between NewAmsterdam Pharma and the Menarini Group to commercialize obicetrapib in Europe. Obicetrapib is a next-generation oral, low-dose and once-daily cholesteryl ester transfer protein (CETP) inhibitor therapeutic candidate, currently in multiple, global phase 3 development for LDL-lowering and cardiovascular events prevention as adjunct treatment in patients with dyslipidemia despite maximally tolerated statin therapy. The collaboration expands Menarini's existing cardiology portfolio of 18 products, which address the most widespread cardiometabolic diseases and aim to prevent and reduce risk factors associated with chronic conditions. Obicetrapib, if approved, could radically alter the treatment landscape in cardiovascular disease by providing an effective and oral option for hyperlipidemia patients in Europe.
Menarini strengthened its respiratory value proposition with various commercial deals in Asthma and COPD for GSK’s Ellipta’s Portfolio (LABA, LAMA, LAMA/LABA). In addition, Nucala® (mepolizumab) is also included for severe Asthma
Melinta and Menarini have entered into a commercial and co-development agreement for Quofenix®, Vaborem™, Orbactiv® and Minocin® in 68 countries, thus building a high value antinfectives platform.
Venatorx Pharmaceuticals and Menarini Group entered into a commercial agreement for Cefepime-Taniborbactam in 96 countries. Cefepime-taniborbactam is an investigational intravenous (IV) beta-lactam/beta-lactamase inhibitor (BL/BLI) antibiotic combination being developed for the treatment of complicated urinary tract infections (cUTIs), and hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP).
Discover our stories from all over the world
Menarini � un�azienda privata completamente integrata con una lunga storia di collaborazioni di successo in tutto il Mondo. In Menarini abbiamo una conoscenza ed esperienza consolidata frutto della nostra capacità di Ricerca & Sviluppo nelle aree terapeutiche chiave, accompagnate da un�eccellente presenza capillare in tutto il Mondo.
Il nostro Team dedicato di Business Development � impegnato a valutare ed esplorare nuove opportunità innovative.
Scopri le nostre storie da tutto il mondo